Despite the profound clinical success of immune-checkpoint inhibitors, their effectiveness is limited by intrinsic and acquired resistance. Bullman, Zitvogel and colleagues provide their views on two clinical trials modulating the microbiome of immunotherapy-resistant patients with melanoma via transplantation of fecal microbiota from patients who responded to immunotherapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Triangulating nutrigenomics, metabolomics and microbiomics toward personalized nutrition and healthy living
Human Genomics Open Access 08 December 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vetizou, M. et al. Science 350, 1079–1084 (2015).
Sivan, A. et al. Science 350, 1084–1089 (2015).
Routy, B. et al. Science 359, 91–97 (2018).
Gopalakrishnan, V. et al. Science 359, 97–103 (2018).
Matson, V. et al. Science 359, 104–108 (2018).
Baruch, E. N. et al. Science 371, 602–609 (2021).
Davar, D. et al. Science 371, 595–602 (2021).
Tanoue, T. et al. Nature 565, 600–605 (2019).
Derosa, L. et al. Cancer Discov. 11, 2396–2412 (2021).
van Nood, E. et al. N. Engl. J. Med. 368, 407–415 (2013).
Taur, Y. et al. Sci. Transl. Med. 10, eaap9489 (2018).
Pires da Silva, I. et al. Lancet Oncol. 22, 836–847 (2021).
Zaremba, A. et al. Eur. J. Cancer 155, 268–280 (2021).
Arance, A.M. et al. J. Clin. Oncol. https://doi.org/10.1200/JCO.2021.39.15_suppl.9504 (2021)
Seitter, S.J. et al. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-1171 (2021).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
S.B. has consulted for GlaxoSmithKline and BiomX; and is on the cancer program–scientific advisory board for BiomX. A.E. has received honoraria from Agenus, Biocad, BMS, BioInvent, CatalYm, CyteImmune, Dash Therapeutics, Ellipses, GlaxoSmithKline, IO Biotech, ISA Pharmaceuticals, Merck/Merck Sharp & Dohme, Nektar, Novartis, Pfizer, Sairopa, SkylineDx, Sellas, TigaTx and TTxDiscovery; and has stock options with CytImmune, Dash Therapeutics, IO Biotech, Sairopa, SkylineDx and Theranovir. C.D.J has consulted for Seres Therapeutics and Azitra. L.Z. is the founder of EverImmune, a biotechnology company involved in the cancer/microbiome space; is a member of the board of directors of Transgene and a member of the scientific advisory boards of Transgene and Sanofi; has research contracts with Daichi Sankyo, TRex, 9 Meters Biopharma and EverImmune; has received honoraria from Transgene; and is an employee of: Gustave Roussy and Faculté de Médecine Paris XI.
Rights and permissions
About this article
Cite this article
Bullman, S., Eggermont, A., Johnston, C.D. et al. Harnessing the microbiome to restore immunotherapy response. Nat Cancer 2, 1301–1304 (2021). https://doi.org/10.1038/s43018-021-00300-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00300-x
This article is cited by
-
Triangulating nutrigenomics, metabolomics and microbiomics toward personalized nutrition and healthy living
Human Genomics (2023)
-
It’s a wrap for 2021!
Nature Cancer (2021)